Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets - PubMed (original) (raw)

Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets

Nora T Kizer et al. Int J Gynecol Cancer. 2015 Jul.

Abstract

Objective: This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer.

Methods: From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 10⁹/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ² Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival.

Results: There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56-1.88, P = 0.93).

Conclusions: Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 10⁹/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement:

None of the authors has a conflict of interest to disclose in regards to this study and its findings.

Figures

Figure 1

Figure 1

Cancer specific survival according to platelet group. Log-rank test p=0.03

Figure 2

Figure 2

Decreased Disease-free survival in patients with thrombocytosis at initial diagnosis. Log-rank p= 0.02

References

    1. Trousseau A. Clinique Medicale de l’Hotel-Dieu de Paris. 2nd ed. Paris France: JB Bailliere & Fils; 1865. Phlegmasia alba dolens; pp. 654–712.
    1. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis of pulmonary embolism. NEJM. 1998;338(17):1169–1173. - PubMed
    1. Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med. 1974;84(5):615–619. - PubMed
    1. Naschitz JE, Heshurum D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer. 1996;77:1759–1767. - PubMed
    1. Scholz HS, Petru E, Gucer F, Haas J, Tamussino K, Winter R. Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res. 2000;20(5C):3983–3985. - PubMed

Publication types

MeSH terms

LinkOut - more resources